Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market
The US FDA approved Aveir VR to treat significant bradycardia on 4 April. It is the world’s only leadless pacemaker with Abbott’s proprietary mapping capability that helps physicians correctly position the device inside the right ventricle.
You may also be interested in...
Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management
Medtech Insight interviewed Leonard Ganz, a veteran cardiac electrophysiologist who recently joined Abbott’s cardiac rhythm management business as its divisional vice president of medical affairs and chief medical officer.
FDA Warns Of Severe Risks Associated With Medtronic Leadless Pacemakers
The US Food and Drug Administration has issued a warning to clinicians of the heightened risk for adverse events, including death, from potential cardiac perforation during implantation of Medtronic’s Micra Transcatheter Pacing System (TPS).
HRS 2020: New Trial Data Support Medtronic’s Micra Pacemaker
The Micra CED study showed a lower rate of complications with the Micra leadless pacemaker than transvenous single-chamber pacemakers.